Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy.
about
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy.Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek populationRisk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers.Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.The diagnosis and treatment of hypertrophic cardiomyopathy.A primer on arrhythmias in patients with hypertrophic cardiomyopathy.Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile.Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathyHeart rate recovery in patients with hypertrophic cardiomyopathy.Hypertrophic cardiomyopathy: infants, children, and adolescents.Systolic compression of epicardial coronary and intramural arteries in children with hypertrophic cardiomyopathy.The prevention of sudden death in hypertrophic cardiomyopathy.Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy.Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations.Device therapy in hypertrophic cardiomyopathy.Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy.Stress echocardiography in valvular heart disease: a current appraisal.Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy.Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease.Linking myofilaments to sudden cardiac death: recent advances.Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis.Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly.Autonomic cardiac control in animal models of cardiovascular diseases II. Variability analysis in transgenic rats with alpha-tropomyosin mutations Asp175Asn and Glu180Gly.Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.Vagal enhancement linking abnormal blood pressure response and subendocardial ischemia in hypertrophic cardiomyopathy.Implantable cardioverter-defibrillator in hypertrophic cardiomyopathyHypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults
P2860
Q33151284-8CFF314D-09CF-414F-B0F3-13EDD6454938Q33157627-60B9FA56-0BE7-44D8-AEFB-6E0DD0FF9573Q33158326-F26319D0-1142-4B6F-8308-17BB87781CB9Q33159927-1975EB15-AE8A-4CD5-A4D3-8B45C7EF57FEQ33159954-EEDC9AA5-FDFD-41D1-BD37-1802BEA848C1Q33161569-EA107AA6-01DB-4B3D-B988-575B6DDAD4B7Q33162730-ECC8B565-073A-4073-9BEF-F4724EE82858Q33167942-B87241EE-5DE0-4C13-907A-1BBF97736EEBQ33651767-BAC84D80-AD8E-4595-B7D1-1C1DDEC8DF38Q33687654-5AC38F8A-C50B-4ED4-B1FE-E77A83664F9AQ34244943-5E3B85B8-B25D-4153-A900-18FD049F72D9Q34452081-B6CE0645-3F33-4269-B33E-0791F7196716Q34628580-648EB3D7-9346-4743-9F9C-4CC91BA7FB1AQ35143411-DCC9C00B-CDCE-47CC-AD9B-CDB96B61A9CCQ37413343-32315A5A-F1A9-41AB-BAE7-4591B52A9B30Q37812384-CC38BE29-C4F3-4FAA-B7E5-37C1C9FC059FQ37926535-3346CA6F-68E0-4967-B630-F892787DDC19Q38349694-BC79F89E-70AB-4CE5-BEFE-E8BCF12B94D2Q38379334-CBEA59D1-C248-4761-91B8-01EE9B78CBFFQ38884022-E13F5F4E-63C3-4923-8CC5-95F9EBB47E08Q39003149-3D873508-BB3A-43A1-AEA2-03E197435573Q39004331-4B3FE11A-E7F1-4D31-A1DA-697E753B8604Q39138183-DA7BFF5F-EC6B-4DE9-BED3-2FC7A756E595Q41696597-A0C19AB0-A096-4BF5-8599-D7EA6CEF3512Q50772874-5C2CDA37-72F4-4F8F-AD7B-63528C8572D7Q51921887-EAA33812-20BE-4C94-B08B-14513E0CA730Q52686171-8238661D-60D8-403E-B6EF-740EF2FDF498Q53082161-49FDEBFF-D4A9-42F0-98B8-3C3A81DCBB2FQ58565538-879C3978-F45A-411C-8AC5-C4A4AB84A430Q58565579-5D211582-1AC1-4A14-AF97-7182A1784BFE
P2860
Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@en
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@nl
type
label
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@en
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@nl
prefLabel
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@en
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@nl
P2093
P1476
Prognostic value of systemic b ...... h hypertrophic cardiomyopathy.
@en
P2093
P304
P356
10.1016/S0735-1097(99)00094-7
P407
P577
1999-06-01T00:00:00Z